Amicus Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Amicus Therapeutics, Inc. - overview
Established
2002
Location
-, NJ, US
Primary Industry
Biotechnology
About
Based in New Jersey, US, and founded in 2002 by John F. Crowley, Amicus Therapeutics, Inc. operates as a biotechnology company providing medicine for rare metabolic diseases, including a rare disease gene therapy. In January 2010, Alzheimer's Drug Discovery Foundation invested USD 0.
21 million in Amicus Therapeutics, Inc. In April 2026, BioMarin Pharmaceutical Inc. acquired Amicus Therapeutics, Inc. for USD 4.
8 billion. Amicus Therapeutics, Inc. developed a product known as galafold, that allows healthcare professionals to treat and diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data. The company offers pombiliti + opfolda for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing.
In addition, the firm provides program known as amicus assist, that provides personalized support to individuals who have been prescribed an Amicus medication.
Current Investors
BioMarin Pharmaceutical Inc., CHL Medical Partners, Frazier Healthcare Partners
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Epidemiology, Pharmaceutical Research & Development
Website
www.amicusrx.com
Verticals
Manufacturing
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Amicus Therapeutics, Inc. - timeline of key events
Amicus Therapeutics, Inc. - financials
| Fiscal Year Ended | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 18,411,000 | 363,000 | 1,224,000 | - | 4,958,000 | 36,930,000 | 91,245,000 | 182,237,000 | 260,886,000 | 305,514,000 | 329,233,000 | - | - | - |
| % Revenue Growth (YoY) | - | (98.0%) | 237.2% | (100.0%) | - | 644.9% | 147.1% | 99.7% | 43.2% | 17.1% | 7.8% | - | - | - |
| EBITDA (USD) | (51,226,000) | (62,462,000) | (67,154,000) | (128,604,000) | (178,648,000) | (438,392,000) | (313,585,000) | (296,716,000) | (236,358,000) | (197,735,000) | (204,144,000) | - | - | - |
| Operating Income (USD) | (52,931,000) | (64,181,000) | (68,701,000) | (130,437,000) | (181,890,000) | (441,985,000) | (328,777,000) | (304,037,000) | (246,998,000) | (206,434,000) | (212,120,000) | - | - | - |
| Operating Margin | (287.5%) | (17680.7%) | (5612.8%) | - | (3668.6%) | (1196.8%) | (360.3%) | (166.8%) | (94.7%) | (67.6%) | (64.4%) | - | - | - |
| % EBITDA Margin | (278.2%) | (17207.2%) | (5486.4%) | - | (3603.2%) | (1187.1%) | (343.7%) | (162.8%) | (90.6%) | (64.7%) | (62.0%) | - | - | - |
| NET Income (USD) | (48,785,000) | (59,633,000) | (68,926,000) | (132,118,000) | (200,042,000) | (284,002,000) | (348,995,000) | (356,388,000) | (276,852,000) | (250,460,000) | (236,568,000) | - | - | - |
| % Net Margin | (265.0%) | (16427.8%) | (5631.2%) | - | (4034.7%) | (769.0%) | (382.5%) | (195.6%) | (106.1%) | (82.0%) | (71.9%) | - | - | - |
Amicus Therapeutics, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Amicus Therapeutics, Inc. | - | ||||||||
| Private Debt | Announced | Amicus Therapeutics, Inc. | - | ||||||||
| Private Debt | Completed | Amicus Therapeutics, Inc. | - | ||||||||
| Add-on, Trade Sale | Completed | Scioderm | - | ||||||||
| Private Debt | Completed | Amicus Therapeutics, Inc. | - |
Displaying 1 - 5 of 5
Amicus Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.